Conference
Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials
Abstract
BackgroundAlthough the addition of bevacizumab to 1st line chemotherapy provides a significant survival benefit for advanced colorectal cancer, the magnitudes of both advantages and toxicities have not been extensively investigated.MethodsA literature-based meta-analysis was conducted; Hazard Ratios were extracted from randomized trials for primary end-points (Progression Free Survival, PFS, Overall Survival OS). The log of event-based risk …
Authors
Loupakis F; Bria E; Vaccaro V; Cuppone F; Milella M; Carlini P; Cremolini C; Salvatore L; Falcone A; Muti P
Volume
29
Publisher
Springer Nature
Publication Date
December 2010
DOI
10.1186/1756-9966-29-58
Conference proceedings
Journal of Experimental & Clinical Cancer Research
Issue
1
ISSN
0392-9078